Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium

Hussar, Daniel A.; Ahmad, Afsheen

doi:10.1331/japha.2013.13538

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regular treatment with FF/VI combination in stable COPD patients is usually well tolerated. The adverse events reported most often in the short-and long-term clinical studies of FF/VI DPI combination therapy vs placebo in these patients include rinopharyngitis (9%), upper respiratory tract infection (7%), headache (7%) and dysphonia and oropharyngeal candidiasis (5%) [78][79][80][81][82]86,104].…”

Section: Anti-inflammatory Effect Of Fluticasone Furoate/vilanterol Cmentioning

confidence: 99%

Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease

Caramori

Ruggeri

Casolari³

et al. 2017

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Current national and international guidelines for the management of patients with stable chronic obstructive pulmonary disease (COPD) recommend the use of inhaled long-acting bronchodilators, inhaled glucocorticoids and their combinations for maintenance treatment of moderate to severe stable COPD. Areas covered: The role of fluticasone furoate (FF) and vilanterol (VI) once daily combination therapy for the regular treatment of patients with stable COPD is discussed in this review. Expert commentary: The regular treatment of moderate to severe stable COPD with once daily FF/VI combination therapy is effective, as seen in in several large placebo-controlled clinical trials involving many thousands of patients. FF/VI improved lung function, decreased respiratory symptoms and decreased the number of COPD exacerbations, including COPD-related hospitalizations. FF/VI combination therapy has also been approved for this indication in most countries. The use of this combination therapy may significantly decrease the economic costs for some National Health Services.

show abstract

Section: Anti-inflammatory Effect Of Fluticasone Furoate/vilanterol Cmentioning

confidence: 99%

Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease

Caramori

Ruggeri

Casolari³

et al. 2017

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

show abstract

“…The adverse events reported most often in the short- and long-term clinical studies of FF/VI DPI combination therapy versus placebo in the regular treatment of stable COPD include nasopharyngitis (9%), upper respiratory tract infection (7%), headache (7%), and dysphonia and oropharyngeal candidiasis (5%). 46 – 52 , 58 However, in the two longest trials of 1 year duration, both pneumonia and bone fractures were seen more frequently with an FF/VI combination therapy than with VI alone. 52 Although the rate of pneumonia roughly doubled in the groups taking FF, this increase is similar to the increased pneumonia risk described previously with FP and in some studies of budesonide and mometasone.…”

Section: Side Effects and Cost-effectiveness Of Fluticasone Furoate/vmentioning

confidence: 99%

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD

Caramori¹,

Chung

Adcock

2014

COPD

View full text Add to dashboard Cite

Currently, there is no cure for chronic obstructive pulmonary disease (COPD). The limited efficacy of current therapies for COPD indicates a pressing need to develop new treatments to prevent the progression of the disease, which consumes a significant amount of health care resources and is an important cause of mortality worldwide. Current national and international guidelines for the management of stable COPD patients recommend the use of inhaled long-acting bronchodilators, inhaled corticosteroids, and their combination for maintenance treatment of moderate to severe stable COPD. Once-daily fluticasone furoate/vilanterol dry powder inhaler combination therapy has recently been approved by the US Food and Drug Administration and the European Medicines Agency as a new regular treatment for patients with stable COPD. Fluticasone furoate/vilanterol dry powder inhaler combination therapy has been shown to be effective in many controlled clinical trials involving thousands of patients in the regular treatment of stable COPD. This is the first once-daily combination of ultra-long-acting inhaled β2-agonists and inhaled glucocorticoids that is available for the treatment of stable COPD and has great potential to improve compliance to long-term regular inhaled therapy and hence to improve the natural history and prognosis of COPD patients.

show abstract

Implementation of quality by design and green chemistry principles to validate the stability indicating method on UHPLC for the simultaneous quantification of Glycopyrronium, Fluticasone, Vilanterol in inhaled formulation

Beda

2024

Green Analytical Chemistry

View full text Add to dashboard Cite

Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium

Cited by 3 publications

References 0 publications

Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease

Fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease

Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD

Implementation of quality by design and green chemistry principles to validate the stability indicating method on UHPLC for the simultaneous quantification of Glycopyrronium, Fluticasone, Vilanterol in inhaled formulation

Contact Info

Product

Resources

About